Compare BFC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | VIR |
|---|---|---|
| Founded | 1894 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2018 | 2019 |
| Metric | BFC | VIR |
|---|---|---|
| Price | $149.50 | $11.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $163.00 | $20.78 |
| AVG Volume (30 Days) | 45.7K | ★ 1.6M |
| Earning Date | 10-20-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | 11.23 | ★ 17.49 |
| EPS | ★ 3.99 | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $52.75 | $257.66 |
| Revenue Next Year | $29.03 | N/A |
| P/E Ratio | $37.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $119.08 | $4.82 |
| 52 Week High | $159.10 | $11.94 |
| Indicator | BFC | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 56.14 |
| Support Level | $147.07 | $8.43 |
| Resistance Level | $153.72 | $11.77 |
| Average True Range (ATR) | 2.66 | 0.51 |
| MACD | -0.36 | -0.03 |
| Stochastic Oscillator | 19.60 | 59.73 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.